Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM. Marsh RA, et al. Among authors: leemhuis t. Biol Blood Marrow Transplant. 2015 Aug;21(8):1460-70. doi: 10.1016/j.bbmt.2015.04.009. Epub 2015 Apr 10. Biol Blood Marrow Transplant. 2015. PMID: 25865646 Free PMC article.
An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
Marsh RA, Kim MO, Liu C, Bellman D, Hart L, Grimley M, Kumar A, Jodele S, Myers KC, Chandra S, Leemhuis T, Mehta PA, Bleesing JJ, Davies SM, Jordan MB, Filipovich AH. Marsh RA, et al. Among authors: leemhuis t. Biol Blood Marrow Transplant. 2013 Nov;19(11):1625-31. doi: 10.1016/j.bbmt.2013.09.001. Epub 2013 Sep 10. Biol Blood Marrow Transplant. 2013. PMID: 24035782 Free PMC article.
Post-Transplant CD34+ Selected Stem Cell "Boost" for Mixed Chimerism after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Children and Young Adults with Primary Immune Deficiencies.
Chandra S, Bleesing JJ, Jordan MB, Grimley MS, Khandelwal P, Davies SM, Edwards S, Leemhuis T, Marsh RA. Chandra S, et al. Among authors: leemhuis t. Biol Blood Marrow Transplant. 2018 Jul;24(7):1527-1529. doi: 10.1016/j.bbmt.2018.03.013. Epub 2018 Mar 16. Biol Blood Marrow Transplant. 2018. PMID: 29555312 Free article.
Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.
Mehta PA, Davies SM, Leemhuis T, Myers K, Kernan NA, Prockop SE, Scaradavou A, O'Reilly RJ, Williams DA, Lehmann L, Guinan E, Margolis D, Baker KS, Lane A, Boulad F. Mehta PA, et al. Among authors: leemhuis t. Blood. 2017 Apr 20;129(16):2308-2315. doi: 10.1182/blood-2016-09-743112. Epub 2017 Feb 8. Blood. 2017. PMID: 28179273 Free PMC article. Clinical Trial.
CD38brightCD8+ T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells.
Khandelwal P, Chaturvedi V, Owsley E, Lane A, Heyenbruch D, Lutzko CM, Leemhuis T, Grimley MS, Nelson AS, Davies SM, Jordan MB, Marsh RA. Khandelwal P, et al. Among authors: leemhuis t. Biol Blood Marrow Transplant. 2020 Jan;26(1):1-6. doi: 10.1016/j.bbmt.2019.08.008. Epub 2019 Aug 20. Biol Blood Marrow Transplant. 2020. PMID: 31442594 Free article.
Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted.
Rubinstein JD, Zhu X, Leemhuis T, Pham G, Ray L, Emberesh S, Jodele S, Thomas S, Cancelas JA, Bollard CM, Hanley PJ, Keller MD, Grimley O, Clark D, Clark T, Lindestam Arlehamn CS, Sette A, Davies SM, Nelson AS, Grimley MS, Lutzko C. Rubinstein JD, et al. Among authors: leemhuis t. Blood Adv. 2021 Sep 14;5(17):3309-3321. doi: 10.1182/bloodadvances.2021004456. Blood Adv. 2021. PMID: 34473237 Free PMC article. Clinical Trial.
Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients.
Rubinstein JD, Jodele S, Heyenbruch D, Wilhelm J, Thomas S, Lutzko C, Zhu X, Leemhuis T, Cancelas JA, Keller M, Bollard CM, Hanley PJ, Boghdadly ZE, Mims A, Davies SM, Grimley MS, Nelson AS. Rubinstein JD, et al. Among authors: leemhuis t. Transplant Cell Ther. 2022 Feb;28(2):116.e1-116.e7. doi: 10.1016/j.jtct.2021.11.005. Epub 2021 Nov 14. Transplant Cell Ther. 2022. PMID: 34785398 Free article.
Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
Rubinstein JD, Lutzko C, Leemhuis T, Zhu X, Pham G, Ray L, Thomas S, Dourson C, Wilhelm J, Lane A, Cancelas JA, Lipps D, Ferrell J, Hanley PJ, Keller MD, Bollard CM, Wang YM, Davies SM, Nelson AS, Grimley MS. Rubinstein JD, et al. Among authors: leemhuis t. Blood Adv. 2022 May 10;6(9):2897-2907. doi: 10.1182/bloodadvances.2021006309. Blood Adv. 2022. PMID: 35108727 Free PMC article. Clinical Trial.
EBV-directed viral-specific T-lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects.
Rubinstein JD, Burns K, Absalon M, Lutzko C, Leemhuis T, Chandra S, Hanley PJ, Keller MD, Davies SM, Nelson A, Grimley M. Rubinstein JD, et al. Among authors: leemhuis t. Pediatr Blood Cancer. 2020 Mar;67(3):e28126. doi: 10.1002/pbc.28126. Epub 2019 Dec 18. Pediatr Blood Cancer. 2020. PMID: 31850668
45 results